PhoenixBio Co., Ltd.

Tokyo Stock Exchange 6190.T

PhoenixBio Co., Ltd. Return on Equity (ROE) for the year ending March 31, 2024: 1.47%

PhoenixBio Co., Ltd. Return on Equity (ROE) is 1.47% for the year ending March 31, 2024, a -95.50% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • PhoenixBio Co., Ltd. Return on Equity (ROE) for the year ending March 31, 2023 was 32.57%, a 169.53% change year over year.
  • PhoenixBio Co., Ltd. Return on Equity (ROE) for the year ending March 31, 2022 was -46.85%, a -115.34% change year over year.
  • PhoenixBio Co., Ltd. Return on Equity (ROE) for the year ending March 31, 2021 was -21.76%, a 39.09% change year over year.
  • PhoenixBio Co., Ltd. Return on Equity (ROE) for the year ending March 31, 2020 was -35.72%.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
SV Wall Street
Tokyo Stock Exchange: 6190.T

PhoenixBio Co., Ltd.

CEO Takashi Shimada
IPO Date March 18, 2016
Location Japan
Headquarters 3-4-1 Kagamiyama
Employees 70
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

StockViz Staff

February 10, 2025

Any question? Send us an email